SK Biopharmaceuticals Co., Ltd.
326030
Clasificación en acciones
#4040
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Precio por acción
$51.65
Capitalización bursátil
$4.05B
Cambio (1 día)
0.27%
Cambio (1 año)
-30.95%
País
KR
Comercio SK Biopharmaceuticals Co., Ltd. (326030)
Categoría
Healthcare
Número de acciones en circulación de SK Biopharmaceuticals Co., Ltd. (326030)
Número de acciones en circulación al June 2026: 78.31M
Según los últimos informes financieros y el precio de las acciones de SK Biopharmaceuticals Co., Ltd., el número actual de acciones en circulación es 78.31M. Al final de December 2024, la empresa tenía 78.31M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de SK Biopharmaceuticals Co., Ltd. (326030) desde 2011 hasta 2026
Acciones en circulación al final de cada año
| Año | Acciones en circulación | Cambiar |
|---|---|---|
| 2026 (TTM) | 78.31M | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 78.31M | 0.00% |
| 2023 | 78.31M | 0.00% |
| 2022 | 78.31M | 0.00% |
| 2021 | 78.31M | 9.12% |
| 2020 | 71.77M | 10.41% |
| 2019 | 65.00M | 4.44% |
| 2018 | 62.23M | 24.47% |
| 2017 | 50.00M | -0.04% |
| 2016 | 50.02M | 0.04% |
| 2015 | 50.00M | 1.08% |
| 2014 | 49.46M | 23.66% |
| 2013 | 40.00M | -0.03% |
| 2012 | 40.01M | 0.11% |
| 2011 | 39.97M | 0.00% |
Acciones en circulación de empresas similares o competidores
| Empresa | Acciones en circulación | Diferencia | País |
|---|---|---|---|
| 253.90M | 224.21% |
US
|
|
| 396.00M | 405.66% |
US
|
|
| 478.91M | 511.54% |
AU
|
|
| 62.19M | -20.59% |
NL
|
|
| - | - |
CH
|
